Hematologic Malignancy
Acute Promyelocytic Leukemia
CI-CAN-00008681APL · APMLExplore in graph →
Hematologic14 active trials2 approved drugs16 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008681APL · APMLExplore in graph →
Clinical trials
89 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02390635 | PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06882031 | Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia | completed | Phase 1 | 12 | SDK Therapeutics, Inc.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | suspended | Phase 1 | 16 | Syros PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT01031368 | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 29 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
| NCT02086773 | Red Cell Transfusion Goals in Patients With Acute Leukemias | completed | Phase 1 | 90 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT00602225 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias(POE07-01) | terminated | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 15, 2018 | clinicaltrials |
| NCT01902329 | A Safety Study of SGN-CD33A in AML Patients | completed | Phase 1 | 195 | Seagen Inc.INDUSTRY | 1 | Jan 5, 2018 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT00217646 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT01132586 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00985530 | Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00301938 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00077467 | Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00357305 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00005064 | PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006213 | BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00042796 | Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00098826 | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Apr 17, 2026source: clinicaltrials